Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H35NO11.ClH |
Molecular Weight | 670.103 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(=O)C4=C(C=CC=C4OC)C3=O)C(O)=C12)C(=O)CO)O[C@H]5C[C@H](N)[C@H](OCC6=CC=CC=C6)[C@H](C)O5
InChI
InChIKey=GPMIHHFZKBVWAZ-LMMKTYIZSA-N
InChI=1S/C34H35NO11.ClH/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40;/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3;1H/t16-,20-,22-,24-,33+,34-;/m0./s1
Berubicin, an anthracycline derivative, is a DNA binding agent and potent topoisomerase II poison. Reata Pharmaceuticals were developing it as a treatment for brain cancer as it can breach the blood-brain barrier. It had also been in early clinical trials for the treatment of lung cancer and malignant gliomas. However, studies have been terminated. In October 2006, it was granted orphan drug designation from the FDA for the treatment of malignant gliomas. According to a CNS Pharmaceuticals media release in April 2018, berubicin will be studied for glioblastoma patients, these investigations will be funded in part by an equity crowdfunding campaign.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1594
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
||
|
FDA ORPHAN DRUG |
227606
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000029091
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
DTXSID10951913
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
C61568
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110580
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
TT-08
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
9874591
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
293736-67-1
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
DB05920
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY | |||
|
7BA3X03948
Created by
admin on Fri Dec 15 15:56:20 GMT 2023 , Edited by admin on Fri Dec 15 15:56:20 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD